Table 4.
Summary of Changes in Patients with Baseline CrCl >50 ml/min that Shifted to ≤50 ml/min
| Day 4 | Day 7 | End of Therapy | Lowest CrCla | |||||
|---|---|---|---|---|---|---|---|---|
| TLV Group (n = 412) | VAN Group (n = 416) | TLV Group (n = 296) | VAN Group (n = 291) | TLV Group (n = 474) | VAN Group (n = 482) | TLV Group (n = 481) | VAN Group (n = 486) | |
| No. (%) | 35 (8.5) | 12 (2.9) | 23 (7.8) | 21 (7.2) | 68 (14.3) | 53 (11.0) | 92 (19.1) | 77 (15.8) |
| % difference (95% CI) | 5.6 (2.5, 8.9)b | 0.6 (−3.8, 4.9) | 3.4 (−0.9, 7.6) | 3.3 (−1.5, 8.1) | ||||
% difference = %TLV–%VAN * 100. TLV = telavancin; VAN = vancomycin; CrCl = creatinine clearance; CI = confidence interval.
a
Lowest CrCl was estimated from serum creatinine concentration measured at any time after baseline (including times not reported in this analysis).
b
Statistically significant difference (95% CI does not include zero).